Literature DB >> 10678363

Comparison of the genotoxic and apoptosis-inducing properties of ganciclovir and penciclovir in Chinese hamster ovary cells transfected with the thymidine kinase gene of herpes simplex virus-1: implications for gene therapeutic approaches.

R Thust1, M Tomicic, R Klöcking, N Voutilainen, P Wutzler, B Kaina.   

Abstract

We studied the genotoxic and apoptosis-inducing properties of ganciclovir (GCV) and penciclovir (PCV) using Chinese hamster ovary cells stably transfected with the thymidine kinase (tk) gene of herpes simplex virus-1 (HSV-1). Cells expressing HSVtk were 300 and 100 times more sensitive than their isogenic HSVtk- counterparts to the cytotoxic effects of GCV and PCV, respectively. Using radiolabeled drugs, GCV was found to be incorporated into the genomic DNA much more effectively than PCV. GCV was highly potent in inducing chromosomal aberrations compared with PCV, which provoked less sister chromatid exchanges and chromosomal changes using equimolar or equitoxic doses. For both agents, apoptosis was shown to be the major route of cell killing. Time course experiments revealed that neither genotoxicity nor apoptosis were induced within the cell cycle exposed to the drug; they are late events provoked in the following cell cycle(s). This indicates that the incorporation/exposure step of GCV or PCV into DNA is not decisive for triggering genotoxicity and apoptosis, but that events occurring subsequently, presumably during replication of a DNA containing the nucleotide analogs, are of major importance. Because PCV, unlike GCV, induced highly effectively apoptosis without exerting much genotoxicity, the use of PCV as a relatively safe alternative drug for suicide gene therapy of malignant diseases is recommended.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10678363     DOI: 10.1038/sj.cgt.7700106

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  9 in total

Review 1.  Regulation and function of adult neurogenesis: from genes to cognition.

Authors:  James B Aimone; Yan Li; Star W Lee; Gregory D Clemenson; Wei Deng; Fred H Gage
Journal:  Physiol Rev       Date:  2014-10       Impact factor: 37.312

2.  Outflow tract ablation using a conditionally cytotoxic feline immunodeficiency viral vector.

Authors:  Ze Zhang; Amardeep S Dhaliwal; Harry Tseng; James D Kim; Joel S Schuman; Robert N Weinreb; Nils A Loewen
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-18       Impact factor: 4.799

3.  Targeted cytosine deaminase-uracil phosphoribosyl transferase suicide gene therapy induces small cell lung cancer-specific cytotoxicity and tumor growth delay.

Authors:  Camilla L Christensen; Torben Gjetting; Thomas T Poulsen; Frederik Cramer; Jack A Roth; Hans S Poulsen
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

Review 4.  Introduction to the background, principles, and state of the art in suicide gene therapy.

Authors:  Ion Niculescu-Duvaz; Caroline J Springer
Journal:  Mol Biotechnol       Date:  2005-05       Impact factor: 2.695

5.  Alteration of the carbohydrate for deoxyguanosine analogs markedly changes DNA replication fidelity, cell cycle progression and cytotoxicity.

Authors:  Jessica J O'Konek; Brendon Ladd; Sheryl A Flanagan; Mike M Im; Paul D Boucher; Tico S Thepsourinthone; John A Secrist; Donna S Shewach
Journal:  Mutat Res       Date:  2010-01-08       Impact factor: 2.433

6.  Inhibition of homologous recombination with vorinostat synergistically enhances ganciclovir cytotoxicity.

Authors:  Brendon Ladd; Jeffrey J Ackroyd; J Kevin Hicks; Christine E Canman; Sheryl A Flanagan; Donna S Shewach
Journal:  DNA Repair (Amst)       Date:  2013-11-11

7.  Unrepairable DNA double-strand breaks initiate cytotoxicity with HSV-TK/ganciclovir.

Authors:  B Ladd; J J O'Konek; L J Ostruszka; D S Shewach
Journal:  Cancer Gene Ther       Date:  2011-08-26       Impact factor: 5.987

8.  Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy).

Authors:  William A. Denny
Journal:  J Biomed Biotechnol       Date:  2003

9.  Optimization of Thymidine Kinase-Based Safety Switch for Neural Cell Therapy.

Authors:  Manon Locatelli; Flavien Delhaes; Ophélie Cherpin; Margaret E Black; Stéphanie Carnesecchi; Olivier Preynat-Seauve; Youssef Hibaoui; Karl-Heinz Krause
Journal:  Cells       Date:  2022-01-31       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.